tldrdaily.news logo
Tag

Poseida Therapeutics

All articles tagged with #poseida therapeutics

business1 year ago

Roche Acquires Poseida for $1.5B, Boosting CAR-T Therapy Access

Roche has agreed to acquire Poseida Therapeutics for $1.5 billion, integrating Poseida's CAR-T therapies and manufacturing capabilities into its Pharmaceuticals Division. The deal includes a tender offer for Poseida's shares at $9 each, with potential milestone payments. The acquisition, approved by both companies' boards, is expected to close in Q1 2025, enhancing Roche's cell therapy development in oncology, immunology, and neurology.

via Yahoo Finance|
#acquisition#business#car-t-therapies
business1 year ago

Roche Acquires Poseida Therapeutics in $1.5B Deal to Expand CAR-T Access

Poseida Therapeutics, a clinical-stage biopharmaceutical company, has agreed to be acquired by Roche Holdings for up to $1.5 billion. Poseida stockholders will receive $9.00 per share in cash at closing, plus a contingent value right for up to an additional $4.00 per share. The acquisition will enhance Roche's capabilities in allogeneic cell therapy, particularly in CAR-T programs for cancer and autoimmune diseases. The transaction is expected to close in the first quarter of 2025, pending regulatory approvals and other conditions.

via PR Newswire|
#acquisition#biopharmaceuticals#business
healthcare2 years ago

"Poseida Therapeutics' Allogeneic CAR-T Shows Promising Results in Multiple Myeloma Trial"

Poseida Therapeutics presented positive early results from its Phase 1 trial of P-BCMA-ALLO1, an allogeneic CAR-T therapy, in relapsed/refractory multiple myeloma (RRMM) at the 65th American Society of Hematology (ASH) Annual Meeting. The therapy demonstrated an 82% overall response rate (ORR) and deep clinical responses in heavily pretreated patients, with no graft-vs-host disease (GvHD) or dose-limiting toxicities observed. The therapy also showed promising persistence and differentiation of CAR-T cells, supporting the potential of allogeneic T stem cell memory (TSCM)-rich CAR-T therapies. Poseida Therapeutics plans to continue developing P-BCMA-ALLO1 in partnership with Roche.

via PR Newswire|
#allogeneic-therapy#car-t-therapy#clinical-trial